Related Experiment Video
Updated: Jul 31, 2025
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
Type 1 Diabetes Prevention: a systematic review of studies testing disease-modifying therapies and features linked to
Background:
Type 1 diabetes (T1D) results from immune-mediated destruction of insulin-producing beta cells. Efforts to prevent T1D have focused on modulating immune responses and supporting beta cell health; however, heterogeneity in disease progression and responses to therapies have made these efforts difficult to translate to clinical practice, highlighting the need for precision medicine approaches to T1D prevention.
Methods:
To understand the current state of knowledge regarding precision approaches to T1D prevention, we performed a systematic review of randomized-controlled trials from the past 25 years testing disease-modifying therapies in T1D and/or identifying features linked to treatment response, analyzing bias using a Cochrane-risk-of-bias instrument.
Results:
We identified 75 manuscripts, 15 describing 11 prevention trials for individuals with increased risk for T1D, and 60 describing treatments aimed at preventing beta cell loss in individuals at disease onset. Seventeen agents tested, mostly immunotherapies, showed benefit compared to placebo (only two prior to T1D onset). Fifty-seven studies employed precision analyses to assess features linked to treatment response. Age, measures of beta cell function and immune phenotypes were most frequently tested. However, analyses were typically not prespecified, with inconsistent methods reporting, and tended to report positive findings.
Conclusions:
While the quality of prevention and intervention trials was overall high, low quality of precision analyses made it difficult to draw meaningful conclusions that inform clinical practice. Thus, prespecified precision analyses should be incorporated into the design of future studies and reported in full to facilitate precision medicine approaches to T1D prevention.
Plain Language Summary:
Type 1 diabetes (T1D) results from the destruction of insulin-producing cells in the pancreas, necessitating lifelong insulin dependence. T1D prevention remains an elusive goal, largely due to immense variability in disease progression. Agents tested to date in clinical trials work in a subset of individuals, highlighting the need for precision medicine approaches to prevention. We systematically reviewed clinical trials of disease-modifying therapy in T1D. While age, measures of beta cell function, and immune phenotypes were most commonly identified as factors that influenced treatment response, the overall quality of these studies was low. This review reveals an important need to proactively design clinical trials with well-defined analyses to ensure that results can be interpreted and applied to clinical practice.
Insights
Precision medicine for Type 1 diabetes (T1D) prevention is needed due to varied disease progression. While some therapies show promise, low-quality precision analyses in trials hinder clinical application, emphasizing the need for better study design.
Area of Science:
- Immunology
- Endocrinology
- Clinical Trials
Background:
- Type 1 diabetes (T1D) arises from immune destruction of pancreatic beta cells, leading to insulin dependence.
- Current T1D prevention strategies face challenges due to disease heterogeneity and variable treatment responses.
- Precision medicine approaches are crucial for effective T1D prevention and management.
Approach:
- A systematic review of randomized-controlled trials over 25 years was conducted to assess disease-modifying therapies for T1D prevention.
- Cochrane risk-of-bias instrument was used to analyze bias in identified studies.
- Focus was on trials testing therapies in individuals at risk for T1D or at disease onset.
Key Points:
- Seventy-five manuscripts were reviewed, including 15 prevention trials and 60 intervention studies.
- Seventeen agents, primarily immunotherapies, demonstrated benefit over placebo, with few showing efficacy before T1D onset.
- Precision analyses frequently examined age, beta cell function, and immune phenotypes, but often lacked prespecification and consistent reporting.
Conclusions:
- High-quality trials exist for T1D prevention and intervention, but precision analyses are often of low quality.
- Meaningful conclusions for clinical practice are difficult to draw due to limitations in precision analysis methodology.
- Future T1D prevention studies must incorporate prespecified, fully reported precision analyses to advance precision medicine.
